ライフサイエンスコーパス: glycogen synthase kinase

1 Here we show that glycogen synthase kinase 3 (GSK-3) interacts with and ph

2 a-catenin pathway through phosphorylation of glycogen synthase kinase 3 (GSK-3), suggesting that this

3 racellular signal-regulated kinase (ERK) and glycogen synthase kinase 3 (GSK-3).

4 Glycogen synthase kinase 3 (GSK-3, isoforms alpha and be

5 ugh alpha-catenin and the kinase activity of glycogen synthase kinase 3 (GSK-3beta).

6 ignalling pathway or dual inhibition (2i) of glycogen synthase kinase 3 (Gsk3) and mitogen-activated

7 We show that glycogen synthase kinase 3 (GSK3) and protein arginine m

8 cells due to its constant phosphorylation by glycogen synthase kinase 3 (GSK3) and subsequent proteas

9 Inhibitors of glycogen synthase kinase 3 (GSK3) are being explored as

10 Here we show how inhibiting glycogen synthase kinase 3 (GSK3) can improve the differ

11 ition of protein kinase C-beta (PKCbeta) and glycogen synthase kinase 3 (GSK3) causes synergistic apo

12 ng approaches, we show how the activation of glycogen synthase kinase 3 (GSK3) contributes to neurona

13 differentiation through negatively affecting glycogen synthase kinase 3 (GSK3) function.

14 Herein, we investigated the role of glycogen synthase kinase 3 (GSK3) in liver regeneration

15 Appropriate temporal application of a glycogen synthase kinase 3 (GSK3) inhibitor combined wit

16 Glycogen synthase kinase 3 (GSK3) inhibitors were identi

17 Here we report that glycogen synthase kinase 3 (GSK3) inhibits AMPK function

18 Glycogen synthase kinase 3 (GSK3) is a genetically valid

19 Here we show that glycogen synthase kinase 3 (Gsk3) is a metabolic sensor

20 Phosphorylation of glycogen synthase kinase 3 (GSK3) isoforms alpha/beta by

21 phosphodegron (CPD) signal, a target site of glycogen synthase kinase 3 (GSK3) kinase and Fbw7 ubiqui

22 Previous studies have indicated that glycogen synthase kinase 3 (GSK3) may play a role in APP

23 We also demonstrate that the kinase glycogen synthase kinase 3 (GSK3) mediates the FBW7-depe

24 Here, we show the expression of the Glycogen synthase kinase 3 (GSK3) MoGSK1 in M. oryzae is

25 we demonstrate a potent effect of inhibiting glycogen synthase kinase 3 (GSK3) on definitive endoderm

26 lt gastric epithelium via deletion of either glycogen synthase kinase 3 (GSK3) or APC or via expressi

27 Suppression of glycogen synthase kinase 3 (GSK3) or FBXW7 rescued Mcl-1

28 PX-866 treatment abolished AKT/glycogen synthase kinase 3 (GSK3) phosphorylation, and c

29 Glycogen synthase kinase 3 (GSK3) plays a central role i

30 We also found that glycogen synthase kinase 3 (GSK3) regulated amyloid-beta

31 itor pools and plays a key role in mediating glycogen synthase kinase 3 (GSK3) signaling during brain

32 Here, we report that Wnt/glycogen synthase kinase 3 (GSK3) signaling functions po

33 Glycogen synthase kinase 3 (GSK3), a prominent enzyme in

34 clock proteins by casein kinase 1 (CK1) and glycogen synthase kinase 3 (GSK3), appear conserved amon

35 Moreover, we show that glycogen synthase kinase 3 (GSK3), rather than mammalian

36 stabilizing many proteins phosphorylated by glycogen synthase kinase 3 (GSK3).

37 diated degradation due to phosphorylation by glycogen synthase kinase 3 (Gsk3).

38 gers a rapid lack of VDAC phosphorylation by glycogen synthase kinase 3 (GSK3).

39 ed that RNPC1 is phosphorylated at Ser195 by glycogen synthase kinase 3 (GSK3).

40 mine analogues which are inhibitors of human glycogen synthase kinase 3 (GSK3).

41 mitochondrial respiratory quiescence through glycogen synthase kinase 3 (GSK3).

42 We show that this process is dependent on glycogen synthase kinase 3 (GSK3): GSK3 was associated w

43 : it increases Akt phosphorylation, inhibits glycogen synthase kinase 3 activity, reduces IkappaB pho

44 hatidylinositol-dependent kinase 1 regulates glycogen synthase kinase 3 activity: a novel mechanism o

45 Acute responses of ERK1/2, p38, Akt, and glycogen synthase kinase 3 after mechanical stress were

46 evealed increased phosphorylation of AKT and glycogen synthase kinase 3 beta (GSK-3beta) in both the

47 Glycogen synthase kinase 3 beta (GSK-3beta) is a central

48 The BCR attenuates glycogen synthase kinase 3 beta (GSK3beta) activity to s

49 Glycogen synthase kinase 3 beta (GSK3beta) is a critical

50 Glycogen synthase kinase 3 beta (GSK3beta) is highly ina

51 We identify an interaction of BMP and Wnt/glycogen synthase kinase 3 beta (GSK3beta) pathways via

52 dulate the activity of Tankyrase enzymes and glycogen synthase kinase 3 beta (GSK3beta), additional t

53 activator of smoothened, and phosphorylated glycogen synthase kinase 3 beta (pGSK-3B), an inactive f

54 on on Ser(552), a site that differs from the glycogen synthase kinase 3 beta phosphorylation site.

55 ibition of the pro-apoptotic molecules, JNK, glycogen synthase kinase 3 beta, or caspases, toxicity i

56 evealed a role for heat shock protein 90 and glycogen synthase kinase 3 but not casein kinase 1 nor L

57 blocked cardiomyocyte specification, whereas glycogen synthase kinase 3 inhibition at this point enha

58 nt which was suppressed by co-treatment with glycogen synthase kinase 3 inhibitor SB216763.

59 thermore, sequential treatment of hPSCs with glycogen synthase kinase 3 inhibitors followed by induci

60 Our data reveal that glycogen synthase kinase 3 signaling also regulates eEF2

61 way seems to occur from Dishevelleds to axin/glycogen synthase kinase 3(GSK3)/beta-catenin complexes

62 an be phosphorylated and stabilized by GSK3 (GLYCOGEN SYNTHASE KINASE 3)-like kinase BIN2 (BRASSINOST

63 (+) NPCs with a pharmacological inhibitor of glycogen synthase kinase 3, a known regulator of WNT sig

64 in sensitivity likely through increased Akt, glycogen synthase kinase 3, and AMPK phosphorylation; an

65 in kinase and the Akt-mediated inhibition of glycogen synthase kinase 3, critical inhibitors of Smad

66 inhibition of Janus kinase 1, inhibition of Glycogen synthase kinase 3, or addition of NRG1 signific

67 y treating SH-SY5Y cells with inhibitors for glycogen synthase kinase 3-beta (GSK3beta) and cyclin-de

68 Insulin/GSK-3beta (glycogen synthase kinase 3-beta) signalling induces cycl

69 TA accelerated beta-catenin degradation by a glycogen synthase kinase 3-beta-dependent mechanism.

70 ytosis enzyme dynamin I via an inhibition of glycogen synthase kinase 3.

71 s of the brassinosteroid (BR) signaling, the glycogen synthase kinase 3/Arabidopsis SHAGGY-like kinas

72 h increased and decreased by manipulation of glycogen synthase kinase-3 (GSK-3) activity.

73 The glycogen synthase kinase-3 (GSK-3) family of serine/thre

74 The role of glycogen synthase kinase-3 (GSK-3) in Alzheimer disease

75 The challenge for glycogen synthase kinase-3 (GSK-3) inhibitor design lies

76 Combining glycogen synthase kinase-3 (GSK-3) inhibitors with VPA o

77 Glycogen synthase kinase-3 (GSK-3) is a constitutively a

78 Glycogen synthase kinase-3 (Gsk-3) is a key regulator of

79 Glycogen synthase kinase-3 (GSK-3) is a key regulator of

80 Glycogen synthase kinase-3 (GSK-3) is essential for many

81 Glycogen synthase kinase-3 (GSK-3) is one of the few sig

82 Glycogen synthase kinase-3 (GSK-3) regulates multiple ce

83 de et al. uses phosphoproteomics to identify glycogen synthase kinase-3 (GSK-3) substrates in mouse e

84 DydA is phosphorylated by glycogen synthase kinase-3 (GSK-3), which is required fo

85 together with inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3), which relieves its i

86 Predictably, inhibition of glycogen synthase kinase-3 (GSK-3), which results from a

87 ling events that result in the inhibition of glycogen synthase kinase-3 (GSK-3)beta represent an adap

88 Intriguingly, glycogen synthase kinase-3 (GSK3) acts centrally, likely

89 ositol-3 kinase/Akt (IRS-PI3K-Akt) pathways, glycogen synthase kinase-3 (GSK3) and mammalian target o

90 T3 signaling, and simultaneous inhibition of glycogen synthase kinase-3 (GSK3) and MAP kinase/ERK kin

91 Glycogen synthase kinase-3 (GSK3) are ubiquitously expre

92 haracterize a novel activation mechanism for glycogen synthase kinase-3 (GSK3) by the sphingolipids p

93 The glycogen synthase kinase-3 (GSK3) family kinases are cen

94 The Axin scaffold and associated glycogen synthase kinase-3 (GSK3) have central roles in

95 Treatment with lithium or a glycogen synthase kinase-3 (GSK3) inhibitor corrects beh

96 ia containing fetal bovine serum (FBS) and a glycogen synthase kinase-3 (GSK3) inhibitor, and in seru

97 Here, we report that glycogen synthase kinase-3 (GSK3) is a critical determin

98 Hippocampal glycogen synthase kinase-3 (GSK3) is hyperactive in the

99 gated the effect of inhibitors targeting the glycogen synthase kinase-3 (GSK3) on the expression of N

100 Moreover, induction of glycogen synthase kinase-3 (GSK3) performed using a Wnt

101 Glycogen synthase kinase-3 (GSK3) regulates many physiol

102 rrent study, we tested whether inhibitors of glycogen synthase kinase-3 (GSK3), previously reported t

103 ogenesis, immunomodulation and regulation of glycogen synthase kinase-3 activity.

104 lian target of rapamycin signaling, glucose, glycogen synthase kinase-3 and liver kinase B1, protein

105 ardiomyocytes in early developmental stages, glycogen synthase kinase-3 and p38 mitogen-activated pro

106 (G6P) and reversible phosphorylation through glycogen synthase kinase-3 and the glycogen-associated f

107 Next, we apply this strategy to study glycogen synthase kinase-3 beta (GSK-3beta), a kinase ab

108 drogenase kinase-1, or its downstream target glycogen synthase kinase-3 did not prevent CCR9 expressi

109 phosphorylated by recombinant GSK3beta; and glycogen synthase kinase-3 inhibitors effectively reduce

110 Glycogen synthase kinase-3 is a Ser/Thr kinase, tonicall

111 enhanced risk for SZ and/or BD can activate glycogen synthase kinase-3 isozymes (GSK3alpha and beta)

112 The glycogen synthase kinase-3 of the parasite (PfGSK-3) was

113 Pharmacological inhibition of glycogen synthase kinase-3 was sufficient to reverse the

114 , while application of Bikinin (inhibitor of glycogen synthase kinase-3), which activated BR signalin

115 lations of AMPK, acetyl CoA carboxylase, and glycogen synthase kinase-3, decreased glycogen synthase

116 ed 4 chemical compound groups: inhibitors of glycogen synthase kinase-3, p38 mitogen-activated protei

117 to ERK1/2 and Akt, including p70 S6-kinase, glycogen synthase kinase-3, ribosomal S6 kinase, c-Jun,

118 hium chloride, a reversible inhibitor of the glycogen synthase kinase-3, that rescued NMJ defects in

119 lation primes for Ser-159 phosphorylation by glycogen synthase kinase-3.

120 E-cadherin, and CD44-mediated signaling and glycogen synthase kinase-3/adenomatous polyposis coli-me

121 Here, we identified a role for glycogen synthase kinase 3alpha (GSK-3alpha) in AML by p

122 y phosphorylated at Thr(714) and Ser(727) by glycogen synthase kinase 3alpha and -beta (GSK-3alpha/be

123 m of this study was to determine the role of glycogen synthase kinase-3alpha (GSK-3alpha) in post-MI

124 We recently demonstrated that glycogen synthase kinase-3alpha (GSK-3alpha) is critical

125 ed by application of a specific inhibitor of glycogen synthase kinase 3beta (6-bromoindirubin-3'-oxim

126 eta-catenin signaling cascades, which switch glycogen synthase kinase 3beta (GSK-3beta) activation on

127 Phosphorylation of tau at Thr212 and glycogen synthase kinase 3beta (GSK-3beta) at Ser9 was r

128 Glycogen synthase kinase 3beta (GSK-3beta) has been sugg

129 Glycogen synthase kinase 3beta (GSK-3beta) is a primary

130 Glycogen synthase kinase 3beta (GSK-3beta) is an enzyme

131 ected T cells and reduces phosphorylation of glycogen synthase kinase 3beta (GSK-3beta), a downstream

132 of cyclin B1, cyclin D3, and phosphorylated glycogen synthase kinase 3beta (GSK-3beta), while infect

133 ion of specific Akt substrates, most notably glycogen synthase kinase 3beta (Gsk-3beta).

134 ound a residue that can be phosphorylated by glycogen synthase kinase 3beta (GSK-3beta).

135 Akt/mammalian target of rapamycin (mTOR) and glycogen synthase kinase 3beta (GSK-3beta)/adenomatous p

136 Consequently, GRbeta-Ad mice had increased glycogen synthase kinase 3beta (GSK3beta) activity and r

137 the c-Jun N-terminal kinase (JNK)-dependent glycogen synthase kinase 3beta (GSK3beta) activity on do

138 , N-methyl-d-aspartate receptor function, or glycogen synthase kinase 3beta (GSK3beta) activity or ex

139 ver, hypoinsulinemia leads to an increase in glycogen synthase kinase 3beta (GSK3beta) activity that,

140 ssociated with insulin resistance, decreased glycogen synthase kinase 3beta (GSK3beta) activity, acti

141 (NF-kappaB) pathway and in the induction of glycogen synthase kinase 3beta (GSK3beta) activity, resu

142 of beta-catenin by enhancing binding between glycogen synthase kinase 3beta (GSK3beta) and beta-caten

143 tcome on different molecular targets such as glycogen synthase kinase 3beta (GSK3beta) and Forkhead b

144 Cellular targets of Li(+), such as glycogen synthase kinase 3beta (GSK3beta) and G proteins

145 Unexpectedly, RNAi-mediated silencing of glycogen synthase kinase 3beta (GSK3beta) and phosphoino

146 oteasomal degradation via phosphorylation by glycogen synthase kinase 3beta (GSK3beta) and recognitio

147 ted protein kinase kinase 4 (MKK4), JNK, and glycogen synthase kinase 3beta (GSK3beta) and thereby de

148 (APC), casein kinase 1alpha (CK1alpha), and glycogen synthase kinase 3beta (GSK3beta) and undergoes

149 In silico kinase prediction revealed glycogen synthase kinase 3beta (GSK3beta) as the most li

150 TGF-beta1 expression and hyperacetylation of glycogen synthase kinase 3beta (GSK3beta) at residue K15

151 tein, HSC70) and causes dephosphorylation of glycogen synthase kinase 3beta (GSK3beta) at Ser 9 by re

152 ects against hepatic steatosis by inhibiting glycogen synthase kinase 3beta (GSK3beta) by enhancing s

153 Glycogen synthase kinase 3beta (GSK3beta) has been shown

154 quent signaling, causing overt activation of glycogen synthase kinase 3beta (GSK3beta) in nerves of m

155 synthesis is associated with inactivation of glycogen synthase kinase 3beta (GSK3beta) in renal cells

156 Glycogen synthase kinase 3beta (GSK3beta) inhibitors, es

157 A member of this family is glycogen synthase kinase 3beta (GSK3beta) interaction pr

158 We show that glycogen synthase kinase 3beta (GSK3beta) interacts with

159 Glycogen synthase kinase 3beta (GSK3beta) is a constitut

160 Inhibition of glycogen synthase kinase 3beta (GSK3beta) is a shared ac

161 At low glucose levels, glycogen synthase kinase 3beta (GSK3beta) is known to ph

162 Glycogen synthase kinase 3beta (GSK3beta) may be critica

163 of TGF-beta receptors and p38 MAPK increased glycogen synthase kinase 3beta (GSK3beta) phosphorylatio

164 ar carcinoma-derived KLF6 mutations affect a glycogen synthase kinase 3beta (GSK3beta) phosphorylatio

165 Here we report that glycogen synthase kinase 3beta (GSK3beta) regulates dend

166 In this study, we demonstrate that glycogen synthase kinase 3beta (GSK3beta) regulates ST2L

167 d by the core clock oscillator BMAL1 and AKT/glycogen synthase kinase 3beta (GSK3beta) signaling path

168 Knockdown of glycogen synthase kinase 3beta (GSK3beta) significantly

169 [e.g., strong bias toward phosphorylation of glycogen synthase kinase 3beta (GSK3beta) via the full-l

170 kt, mammalian target of rapamycin complex 1, glycogen synthase kinase 3beta (GSK3beta), and CREB.

171 e IGF-I, IGF binding protein-1 (IGFBP-1) and glycogen synthase kinase 3beta (GSK3beta), as one major

172 Psychotropic medications target glycogen synthase kinase 3beta (GSK3beta), but the funct

173 ivation, which results in hyperactivation of glycogen synthase kinase 3beta (GSK3beta), followed by p

174 kt pathway, leading to the downregulation of glycogen synthase kinase 3beta (GSK3beta), in wild type

175 The phosphorylation is catalyzed by glycogen synthase kinase 3beta (GSK3beta), ultimately re

176 hic signaling intermediates, such as Akt and glycogen synthase kinase 3beta (GSK3beta), were dephosph

177 y sites in the N-terminus of beta-catenin as glycogen synthase kinase 3beta (GSK3beta), which are rec

178 dent on LFA-1/ICAM-1-induced inactivation of glycogen synthase kinase 3beta (GSK3beta), which is medi

179 PI exposure abrogated glycogen synthase kinase 3beta (GSK3beta)-mediated degra

180 1 interacts with Nrf2 and stabilizes it from glycogen synthase kinase 3beta (GSK3beta)-mediated phosp

181 FN signaling pathways occurs at the point of glycogen synthase kinase 3beta (GSK3beta)-TANK-binding k

182 These include protein kinase A (PKA) and glycogen synthase kinase 3beta (GSK3beta).

183 ivation and this occurs in part by targeting glycogen synthase kinase 3beta (GSK3beta).

184 inhibition of the tumor suppressors PTEN and glycogen synthase kinase 3beta (GSK3beta).

185 n (mTOR) signaling pathway and inhibition of glycogen synthase kinase 3beta (GSK3beta).

186 by increasing the stability and activity of glycogen synthase kinase 3beta (GSK3beta).

187 t VRK2 activity was negatively controlled by glycogen synthase kinase 3beta (GSK3beta).

188 g protein binding protein kinase A (PKA) and glycogen synthase kinase 3beta (GSK3beta).

189 atty acids, and this suppression depended on glycogen synthase kinase 3beta activation and induction

190 Moreover, JNK and glycogen synthase kinase 3beta activation was significan

191 au phosphorylation and solubility, increased glycogen synthase kinase 3beta activity, compromised lon

192 protein that plays a key role in attenuating glycogen synthase kinase 3beta activity, leading to aber

193 2A and recruits protein phosphatase 2A with glycogen synthase kinase 3beta and beta-catenin, inducin

194 Glycogen synthase kinase 3beta and Foxo1 are two PI-3K-r

195 isms involved demonstrate that ASPH binds to glycogen synthase kinase 3beta and inhibits its subseque

196 ibition of ASPH activity, phosphorylation of glycogen synthase kinase 3beta and p16 expression were i

197 reasing Ser9 phosphorylation-inactivation of glycogen synthase kinase 3beta by RBMY, thereby impeding

198 of stable MT subsets through inactivation of glycogen synthase kinase 3beta by the viral Ser/Thr kina

199 ted with release of the inhibitory effect of glycogen synthase kinase 3beta function by decreasing Se

200 in, and that beta-catenin activation through glycogen synthase kinase 3beta inhibition leads to FANCC

201 decreased DJ-1 and increased phosphorylated glycogen synthase kinase 3beta levels may account for im

202 Wnt/beta-catenin pathway by inactivation of glycogen synthase kinase 3beta of NKT cells.

203 in endothelial cells as reflected in Akt and glycogen synthase kinase 3beta phosphorylation, Ras-rela

204 ment, and reduced Akt (protein kinase B) and glycogen synthase kinase 3beta phosphorylation.

205 te-mediated phosphoinositide 3-kinase (PI3K)/glycogen synthase kinase 3beta signaling and decreased a

206 horylation and impaired binding to GSK3beta (glycogen synthase kinase 3beta).

207 increase in phospho-beta-catenin and active glycogen synthase kinase 3beta, a kinase known to target

208 t3a (the canonical activator), inhibitors of glycogen synthase kinase 3beta, and small-interfering RN

209 Akt murine thymoma viral oncogene homolog-1, glycogen synthase kinase 3beta, cyclin-dependent kinase

210 Downstream of glycogen synthase kinase 3beta, cytoplasmic linker-assoc

211 ver, inhibition of protein phosphatase 1 and glycogen synthase kinase 3beta, downstream targets of Ca

212 ced tumor growth, induced phosphorylation of glycogen synthase kinase 3beta, enhanced p16 expression

213 n showed AQP1 interaction with beta-catenin, glycogen synthase kinase 3beta, LRP6, and Axin1.

214 hosphorylation, downstream phosphosubstrates glycogen synthase kinase 3beta, mammalian target of rapa

215 of cyclin-dependent protein kinase 5 (Cdk5), glycogen synthase kinase 3beta, protein phosphatase 1, o

216 e kinase 3beta by RBMY, thereby impeding the glycogen synthase kinase 3beta-dependent degradation of

217 Molecularly, ROCK inhibition induced glycogen synthase kinase 3beta-dependent phosphorylation

218 ta-catenin expression and stabilization in a glycogen synthase kinase 3beta-independent manner.

219 7, p38 mitogen-activated protein kinase, and glycogen synthase kinase 3beta.

220 ) transcriptional activity via inhibition of glycogen synthase kinase 3beta.

221 nalling proteins, protein kinase B (Akt) and glycogen synthase-kinase 3beta, in maternal liver (P < 0

222 -beta(1-40), phospho-tau(Thr 231) and active glycogen synthase kinase-3beta (aGSK-3beta).

223 rexpression of TDP-43 leads to activation of glycogen synthase kinase-3beta (GSK-3beta) and that GSK-

224 dated AD targets beta-secretase (BACE-1) and glycogen synthase kinase-3beta (GSK-3beta) by attacking

225 In addition, application of glycogen synthase kinase-3beta (GSK-3beta) inhibitor com

226 etin, reactivation of beta-catenin using the glycogen synthase kinase-3beta (GSK-3beta) inhibitor LiC

227 Herein we report that glycogen synthase kinase-3beta (GSK-3beta) is phosphoryl

228 Activity of glycogen synthase kinase-3beta (GSK-3beta) is required f

229 Furthermore, activation of glycogen synthase kinase-3beta (GSK-3beta) was required

230 sis coli tumor suppressor protein (APC), and glycogen synthase kinase-3beta (GSK-3beta), which could

231 atocytes, which led to a delayed increase in glycogen synthase kinase-3beta (GSK-3beta)-mediated hepa

232 demonstrate that alcohol intake also blocks glycogen synthase kinase-3beta (GSK-3beta)-phosphorylati

233 ein function are via a pathway that involves glycogen synthase kinase-3beta (GSK-3beta).

234 teins, which were predicted to be targets of glycogen synthase kinase-3beta (GSK-3beta).

235 hase and the phosphorylation (inhibition) of glycogen synthase kinase-3beta (GSK-3beta).

236 hase and the phosphorylation (inhibition) of glycogen synthase kinase-3beta (GSK-3beta).

237 Glycogen synthase kinase-3beta (GSK3beta) activity is in

238 nted pre-synaptic protein deficit, decreased glycogen synthase kinase-3beta (GSK3beta) activity, and

239 finding is the pronounced downregulation of glycogen synthase kinase-3beta (Gsk3beta) and upregulati

240 Glycogen synthase kinase-3beta (GSK3beta) has diverse bi

241 Here we demonstrate that hyperactivity of glycogen synthase kinase-3beta (GSK3beta) in the atrium

242 While glycogen synthase kinase-3beta (GSK3beta) is known to pa

243 Glycogen synthase kinase-3beta (GSK3beta) plays a critic

244 uclear Nrf2 export/degradation machinery via glycogen synthase kinase-3beta (Gsk3beta) signaling was

245 at PAD4 recognizes, binds, and citrullinates glycogen synthase kinase-3beta (GSK3beta), both in vitro

246 lted in increased phosphorylation of Akt and glycogen synthase kinase-3beta (GSK3beta), leading to en

247 tion and insulin secretion via regulation of glycogen synthase kinase-3beta (GSK3beta).

248 s (ankyrin G, EB1) were knocked down or when glycogen synthase kinase-3beta (GSK3beta; an AD-associat

249 sed p38 mitogen-activated protein kinase and glycogen synthase kinase-3beta activity, which are belie

250 panied by hyperphosphorylation of substrates glycogen synthase kinase-3beta and mammalian target of r

251 hase survival pathway, and the inhibition of glycogen synthase kinase-3beta and nuclear factor kappa

252 hase survival pathway, and the inhibition of glycogen synthase kinase-3beta and nuclear factor kappa

253 ion and completely blocked the inhibition of glycogen synthase kinase-3beta gene transcription.

254 Overexpression of Snail1 and inhibition of glycogen synthase kinase-3beta in colorectal tumor cells

255 Such glycogen synthase kinase-3beta inactivation causes chang

256 -beta stimulation of human keratinocytes, by glycogen synthase kinase-3beta inhibition in several epi

257 erentiated hPSCs into mesoderm cells using a glycogen synthase kinase-3beta inhibitor for 3 days, the

258 mbinant Wnt3a protein or CHIR-99021 (CHIR, a glycogen synthase kinase-3beta inhibitor) caused a dose-

259 L is stabilized in a complex with axin1 when glycogen synthase kinase-3beta is overexpressed.

260 ha/wrd pathway in the motoneuron antagonizes glycogen synthase kinase-3beta kinase activity to preven

261 on of GABAergic transmission via D2 receptor-glycogen synthase kinase-3beta signaling dramatically re

262 The phosphorylation and inactivation of glycogen synthase kinase-3beta was dependent on mammalia

263 l as by inhibition of the Akt-GSK-3beta (Akt-glycogen synthase kinase-3beta) pathway.

264 orylation of the inhibitory Ser-9 residue of glycogen synthase kinase-3beta, a primary Tau kinase inv

265 ollowed by phosphorylation (inactivation) of glycogen synthase kinase-3beta, at least in part via STA

266 cyclin D1, E-cadherin, beta-catenin, Dvl-1, glycogen synthase kinase-3beta, axin-1, and adenomatous

267 no changes in Ctnnb1 expression, activity of glycogen synthase kinase-3beta, known to phosphorylate a

268 activator of beta-catenin via inhibition of glycogen synthase kinase-3beta, reversed the inhibition

269 on, and increased phosphorylation of Akt and glycogen synthase kinase-3beta, ultimately resulting in

270 d to the phosphorylation and inactivation of glycogen synthase kinase-3beta, which resulted in inhibi

271 inding (CREB) protein levels to decreaseviaa glycogen synthase kinase-3beta-dependent mechanism.

272 pstream signaling pathways known to regulate glycogen synthase kinase-3beta.

273 ial-mesenchymal transition by repressing AKT/glycogen synthase kinase-3beta/beta-catenin signaling.

274 ological or genetic inhibition of tau kinase glycogen-synthase-kinase-3beta (GSK-3beta).

275 Apc participates in a complex that includes glycogen synthase kinase beta (Gsk3beta) and betacatenin

276 Here we show that the glycogen synthase kinase beta (GSK3beta) expression is e

277 In a previous study, the FGK3 glycogen synthase kinase gene orthologous to mammalian G

278 PKB/Akt in turn inactivates glycogen synthase kinase (GSK) 3, a major regulator of m

279 Studies have implicated signaling through glycogen synthase kinase (GSK) 3alpha/beta in the activa

280 work, we demonstrate that overexpression of glycogen synthase kinase (GSK) 3beta in neural precursor

281 Mechanistically, STAT3 facilitates glycogen synthase kinase (GSK) 3beta-mediated degradatio

282 Here we identify glycogen synthase kinase (GSK) as a novel and critical c

283 Glycogen synthase kinase (GSK)-3 is a ubiquitously expre

284 CRMP-2 and ROCK II is partially regulated by glycogen synthase kinase (GSK)-3 phosphorylation of CRMP

285 The enzymes 5-lipoxygenase (5-LO) and glycogen synthase kinase (GSK)-3 represent promising dru

286 Blast TBI increased glycogen synthase kinase (GSK)-3beta activities in ApoE4

287 These same stimuli enhance glycogen synthase kinase (GSK)-3beta activity through in

288 n vitro and in vivo, working through the Akt/Glycogen Synthase Kinase (GSK)-3beta pathway.

289 Glycogen synthase kinase (GSK)-3beta phosphorylates the

290 eptor is modulated, here, we have found that glycogen synthase kinase (GSK)-3beta phosphorylation of

291 Here, we provide evidence that glycogen synthase kinase (GSK)-3beta promotes cell proli

292 This study addresses the role of glycogen synthase kinase (GSK)-3beta signaling in the tu

293 show that the dual phosphodiesterase (PDE)7- glycogen synthase kinase (GSK)3 inhibitor, VP3.15, a het

294 Mechanistically, Tanshinone IIA blunted glycogen synthase kinase (GSK)3beta overactivity and hyp

295 used to deliver low doses of small molecule glycogen synthase kinase (GSK-3) antagonists that promot

296 sly showed that the serine/threonine kinase, glycogen synthase kinase, GSK-3alpha/beta, is a central

297 exerted its positive effect by inhibition of glycogen synthase kinase (GSK3) activity and enhancement

298 A point mutation in a putative glycogen synthase kinase phosophorylation site within th

299 lates alcohol-induced BK internalization via glycogen synthase kinase phosphorylation.

300 f lithium, in which fine-tuned regulation of glycogen synthase kinase type 3, a prime target for lith